📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Trethera

1.1 - Company Overview

Trethera Logo

Trethera

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of small-molecule therapeutics that control DNA replication and integrity, including TRE-515, an orally bioavailable inhibitor of deoxycytidine kinase (dCK) targeting the nucleotide salvage pathway to treat solid tumors and autoimmune diseases.

Products and services

  • TRE-515: An orally-bioavailable inhibitor of deoxycytidine kinase (dCK) that targets the nucleotide salvage pathway to treat solid tumors and autoimmune diseases
  • Small-Molecule Development: Develops small molecules that control DNA replication and integrity, advancing compounds that modulate DNA replication and integrity
  • Small-Molecule Discovery: Discovers small molecules that control DNA replication and integrity, identifying compounds that modulate DNA replication and integrity

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Trethera

U3 Pharma Logo

U3 Pharma

HQ: Germany Website
  • Description: Provider of targeted cancer drug development and novel targeted therapeutics, based in Martinsried near Munich, Germany. Established in 2001, U3 Pharma develops a pipeline of targeted therapies grounded in discoveries by founder Professor Axel Ullrich. Since May 2008, the company has belonged to DAIICHI Sankyo Co., Ltd.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full U3 Pharma company profile →
Marengo Therapeutics Logo

Marengo Therapeutics

HQ: United States Website
  • Description: Provider of T cell–modulating antibody platforms and therapeutics, including the STAR bi-functional molecule platform pairing anti-Vβ antibodies with costimulatory signals for antigen-rich 'hot' tumors; the TriSTAR T cell engager for antigen-low 'cold' tumors; TCR-targeting antibodies; an antibody technology platform using genomics and TCR sequencing; and STAR0602, in Phase I/II (START-001) for advanced antigen-rich solid tumors.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Marengo Therapeutics company profile →
Cellectis Logo

Cellectis

HQ: France Website
  • Description: Provider of adoptive cancer immunotherapies, developing allogeneic CAR T candidates including UCART22 for r/r B-ALL, UCART123 targeting CD123 for AML, and UCART20x22 targeting CD20/CD22 for B-cell malignancies, plus TALEN gene editing and PulseAgile electroporation technologies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Cellectis company profile →
Rain Oncology Logo

Rain Oncology

HQ: United States Website
  • Description: Provider of precision oncology therapies targeting oncogenic drivers, developing milademetan, an oral small molecule inhibitor of the p53-MDM2 complex for various cancers. Clinical programs include MANTRA (Phase 3 in dedifferentiated liposarcoma), MANTRA-2 (Phase 2 in TP53 wildtype/MDM2-amplified solid tumors), and MANTRA-4 (Phase 1/2 with atezolizumab in CDKN2A loss, TP53 wildtype tumors).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Rain Oncology company profile →
Oncogeni Logo

Oncogeni

HQ: United Kingdom Website
  • Description: Provider of novel cell- and RNA-based cancer medicines, specializing in small interfering RNA and mesodermal killer cells.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Oncogeni company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Trethera

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Trethera

2.2 - Growth funds investing in similar companies to Trethera

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Trethera

4.2 - Public trading comparable groups for Trethera

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Trethera

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Trethera

What does Trethera do?

Trethera is a provider of small-molecule therapeutics that control DNA replication and integrity, including TRE-515, an orally bioavailable inhibitor of deoxycytidine kinase (dCK) targeting the nucleotide salvage pathway to treat solid tumors and autoimmune diseases.

Who are Trethera's competitors?

Trethera's competitors and similar companies include U3 Pharma, Marengo Therapeutics, Cellectis, Rain Oncology, and Oncogeni.

Where is Trethera headquartered?

Trethera is headquartered in United States.

How many employees does Trethera have?

Trethera has 1,000 employees 🔒.

When was Trethera founded?

Trethera was founded in 2010 🔒.

What sector and industry vertical is Trethera in?

Trethera is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Trethera

Who are the top strategic acquirers in Trethera's sector and industry

Top strategic M&A buyers and acquirers in Trethera's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Trethera?

Top strategic M&A buyers groups and sectors for Trethera include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Trethera's sector and industry vertical

Which are the top PE firms investing in Trethera's sector and industry vertical?

Top PE firms investing in Trethera's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Trethera's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Trethera's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Trethera's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Trethera include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Trethera's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Trethera?

The key public trading comparables and valuation benchmarks for Trethera include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Trethera for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Trethera with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Trethera's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Trethera with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Trethera's' sector and industry vertical?

Access recent funding rounds and capital raises in Trethera's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Trethera